Tumor marker may guide chemo choice for rare cancers
NCT ID NCT03217097
First seen Nov 21, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study looked at 116 people with advanced neuroendocrine tumors (NETs) to see if a marker called MGMT can predict which chemotherapy works best. Researchers compared two chemo types—alkylating agents and oxaliplatin—based on the tumor's MGMT status. The goal is to personalize treatment and improve response rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Annecy Genevois
Pringy, 74374, France
-
CHU d'Angers
Angers, 49933, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Hôpital Beaujon - APHP
Clichy, 92118, France
-
Hôpital Claude Hurriet - CHRU Lille
Lille, 59037, France
-
Hôpital Cochin - APHP
Paris, 75014, France
-
Hôpital Edouard Herriot - Hospices Civils de Lyon
Lyon, 69003, France
-
Hôpital Estaing, CHU de Clermont-Ferrand
Clermont-Ferrand, 63003, France
-
Hôpital François Mitterrand - CHU Dijon Bourgogne
Dijon, 21000, France
-
Hôpital Nord - CHU Saint Etienne
Saint-Priest-en-Jarez, 42270, France
-
Hôpital Privé Jean Mermoz
Lyon, 69008, France
-
Hôpital Rangueil - CHU Toulouse
Toulouse, 31059, France
-
Hôpital Robert Debré - CHU Reims
Reims, 51092, France
-
Hôpital Saint Louis - APHP
Paris, 75010, France
-
Hôpital Sud - CHU Amiens
Amiens, 80054, France
-
Hôpital Trousseau - CHU Tours
Tours, 37044, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut Paoli Calmettes
Marseille, 13009, France
-
Institut de Cancérologie de la Loire
Saint-Priest-en-Jarez, 42270, France
Conditions
Explore the condition pages connected to this study.